Clinical Trials Logo

Cancer clinical trials

View clinical trials related to Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03375086 Not yet recruiting - Cancer Clinical Trials

A Study of APX3330 in Patients With Advanced Solid Tumors

APX3330
Start date: January 9, 2018
Phase: Phase 1
Study type: Interventional

This is a Phase 1, multi-center, open-label, dose-escalation oncology study of APX3330 in patients with advanced solid tumors.

NCT ID: NCT03371147 Not yet recruiting - Cancer Clinical Trials

CancerLife: Patient-Driven Solution in Cancer Care

Start date: January 3, 2018
Phase: N/A
Study type: Interventional

The primary purpose of this study is to evaluate the use of a digital information and communication platform (DICP) in improving outcomes in patients with cancer and their caregivers.

NCT ID: NCT03360695 Not yet recruiting - Breast Cancer Clinical Trials

BRIDGE: Proactive Psychiatry Consultation and Case Management for Patients With Cancer

Start date: December 11, 2017
Phase: N/A
Study type: Interventional

The purpose of this research is to understand if it is helpful for patients with mental illness to be connected to a psychiatrist and case manager at the time of cancer diagnosis.

NCT ID: NCT03360474 Not yet recruiting - Cancer Clinical Trials

Implementation of a Delirium Screening

Start date: February 2018
Phase: N/A
Study type: Interventional

The purpose of this project is to improve patient outcomes in individuals affected by cancer, through the implementation of a delirium screening and treatment protocol in the ICU setting. The hypothesis is that patients who receive an accurate and early diagnosis of delirium coupled with a standardized intervention protocol will demonstrate improved patient outcomes as evidenced by fewer days spent in the ICU, fewer days spent in the hospital (overall length of stay) and the need for less sedative medication throughout their ICU stay as compared to patient data prior to the implementation of a delirium protocol.

NCT ID: NCT03357861 Not yet recruiting - Cancer Clinical Trials

Cancer Patients Treated With Immunotherapy in Intensive Care Unit

IMMUNO-REA
Start date: February 1, 2018
Phase: N/A
Study type: Observational

This work aims to describe the characteristics and methods of management of patients suffering from a solid tumor treated with immunotherapy admitted to intensive care.

NCT ID: NCT03356171 Not yet recruiting - Cancer Clinical Trials

Cardiac Coherence Combined With Personal Physical Activity in Patients With Cancer

APACCHE
Start date: January 2018
Phase: N/A
Study type: Interventional

APACCHE (Adapted Physical Activity and Cardiac Coherence in HEmatologic patients) study investigates effects of heart rate variability biofeedback training, combined with classical adapted physical activity, on health-related quality of life in patients previously treated for hematologic malignancies. It is a prospective, randomized clinical trial from University Hospital of Reunion Island. The main objective is evaluated with QLQ-C30 survey score differences.

NCT ID: NCT03352934 Not yet recruiting - Cancer Clinical Trials

Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After Chemotherapy

AveNEC
Start date: November 2017
Phase: Phase 2
Study type: Interventional

The purpose of the AveNEC trial is to investigate the clinical activity and safety of avelumab in patients with NEC G3 (WHO 2010), including "NET G3" who are progressive after first line chemotherapy.

NCT ID: NCT03351140 Not yet recruiting - Cancer Clinical Trials

Patient‐Reported Outcome Measurement Information System (PROMIS) Physical Function

Start date: December 8, 2017
Phase: N/A
Study type: Observational

The objective of this study is to conduct in-person qualitative interviews of subjects who have different tumor types to identify and assess relevant PROMIS physical function items that can be utilized in future studies. Health Research Associates (HRA) will conduct qualitative interviews in subjects with a variety of cancer types. PROMIS is a set of self‐report measurement tools, developed by the United States (US) National Institutes for Health (NIH). The most recent version of PROMIS Physical Function Item Bank contains 165 items assessing a range of abilities and its subset, a 45-item PROMIS Function Cancer Item Bank which contains questions relevant to subjects with cancer. Approximately 150 subjects with five tumor types will be recruited. HRA will conduct the interviews that will be audio-recorded for transcription and analysis. Five tumor types that will be focused on are Breast, Prostate, Non‐Small‐Cell Lung Cancer (NSCLC), Multiple Myeloma, and Diffuse Large B‐Cell (DLBCL) or Follicular Lymphoma. Interviews will be conducted in English language in private areas within clinic site or rented meeting facilities and will last approximately for 60-90 minutes.

NCT ID: NCT03348826 Not yet recruiting - Cancer Clinical Trials

Study of Sodium Bicarbonate in Restoring Blocked Catheters

Start date: December 1, 2017
Phase: Phase 2
Study type: Interventional

This is a study looking at the use of sodium bicarbonate to restore the flow of blocked central line devices in patients with blood cancers. Central line devices uses thin tubes that are placed into a vein in the body to give medicines, fluids, nutrients, blood products, etc. Sometimes, the lines become blocked. The standard procedure to get the line working again is to use alteplase, a protein that dissolves blood clots. While blood clotting is one cause of a blocked line, other reasons included the formation of calcium deposits. Sodium bicarbonate is routinely used in the treatment of patients receiving chemotherapy. Sodium bicarbonate is a liquid drug which is capable of dissolving protein and calcium deposits. This study will compare whether sodium bicarbonate works just as well as alteplase to recover the function of a blocked line.

NCT ID: NCT03347162 Not yet recruiting - Cancer Clinical Trials

Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer

Start date: November 1, 2018
Phase: N/A
Study type: Observational

PURPOSE: To determine the prognostic properties of a comprehensive evaluation of body composition and physical function in patients with GI-HEP cancer from point of diagnosis and throughout the treatment trajectory. GI-HEP: Patients with tumors of the upper gastrointestinal or hepatobiliary tract, specifically tumors of the esophagus, gastro-esophageal junction, stomach, primary tumors of the liver or biliary tract, as well as colorectal liver metastasis or tumors of the pancreas.